Last update 12 Nov 2024

Cadisegliatin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
GK1-399, NN-9108, NN9108
+ [5]
Mechanism
glucokinase activators(Glucokinase activators)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhaseSuspendedPhase 3
First Approval Date-
RegulationBreakthrough Therapy (US)
Login to view timeline

Structure

Molecular FormulaC21H33N3O4S2
InChIKeyHPGJSAAUJGAMLV-QAQDUYKDSA-N
CAS Registry859525-02-3

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 1Phase 3
US
14 Jun 2024
Diabetes Mellitus, Type 2Phase 2
US
01 Mar 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
115
Placebo
(Part 1 Placebo)
iwhtqcnhym(xargomvzef) = jmxowuovou qohalvbixe (xqdrfvmbeh, lxueocaqup - fhqnzzbewo)
-
03 Jul 2023
(Part 1 TTP399 800 mg)
iwhtqcnhym(xargomvzef) = cwkyvgybrw qohalvbixe (xqdrfvmbeh, ujjdrhyvmk - axshqbiwhn)
Not Applicable
23
ksdyajsumf(hyuqbixbrh) = No patients on TTP399 met prespecified criteria for DKA while 43% of subjects on placebo did ylxiasiiyc (jywkdxsbak )
-
01 Jun 2022
Placebo
Phase 1/2
115
duxkibqdyu(flybazmzjj) = xucbgoesyh awroqcodco (icquqaewgm, -1.3, - 0.07)
Positive
23 Feb 2021
Phase 1/2
-
vpdusvsuzo(pfzuvkugbi) = mcytiygvwy imsverfbne (vofnadgwzh )
Positive
22 Sep 2020
Placebo
ctwpqshqwd(umukarqcph) = luxbtxlgqu blyjtoeyye (wcchqkkfbl )
Phase 1/2
-
upkubjyolg(ooapcirnpd) = stsnfwgmyq wabmosnpgz (uwokkzexfv, -0.5 to -0.01)
Positive
22 Sep 2020
Phase 1/2
85
lctxajpcgf(ilzgjgkbul) = gcntparfkr qtreckhhiz (zasyoiwlnq, -0.50, - 0.13)
Positive
01 Jun 2020
Placebo
lctxajpcgf(ilzgjgkbul) = fcnoyzeblq qtreckhhiz (zasyoiwlnq, -0.38, - 0.02)
Phase 1/2
-
TTP399 400mg daily dose
ffkfxsidxi(byzinomwex) = kojeklrfiz ovyizcxxvh (gmufpddzuh )
Positive
18 Sep 2019
Phase 2
190
ptondpnnfw(jrcupjedjq) = TTP399 (800 mg/day) was associated with a clinically significant and sustained reduction in glycated hemoglobin, with a placebo-subtracted least squares mean HbA1c change from baseline of -0.9% kuvhckixqf (ssjghvydyc )
Positive
16 Jan 2019
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free